Pharming Group reports financial results for the first quarter of 2020
Financial updatesPharming Group N.V. presents its (unaudited) financial report for the first quarter of the year ended 31 March 2020.
Pharming Group N.V. presents its (unaudited) financial report for the first quarter of the year ended 31 March 2020.
Pharming Group N.V. announces that it has received formal European Commission approval to treat acute hereditary angioedema (HAE) attacks in children with RUCONEST®. Following the positive opinion and recommendation from the European Medicine Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) on the extension of the indication for RUCONEST® received on 26 March 2020.
Pharming Group N.V. announces encouraging results from five patients with confirmed COVID-19 (SARS-CoV-2) infections hospitalized with related severe pneumonia that were treated with RUCONEST® (recombinant human C1 inhibitor) under a compassionate use program at the University Hospital Basel, Switzerland.
Pharming Group N.V. invites its shareholders to the 2020 Annual General Meeting (AGM) to be held at 14:00 CET on 20 May 2020
Call slides now available for download.
Annual Report 2019 is available for download on the Pharming website today
Pharming Group N.V. announces the Committee for Medicinal Products for Human Use (CHMP), an advisory committee of the European Medicine Agency (EMA), has adopted a positive opinion recommending an extension of the indication for RUCONEST® to the European Commission.
Pharming Group N.V. announces that it has been included in the Euronext Amsterdam Midkap index (AMX).
Pharming Group N.V. today announced that its Chief Financial Officer, Robin Wright, has decided (for family reasons) not to put himself up for re-election as a member of the Board of Management and thus as Chief Financial Officer at the upcoming General Meeting of Shareholders on 20 May 2020 and that, as result of this decision, his term with the Company will end as at that date.
Pharming Group N.V. today announced it has also received US Food and Drug Administration (FDA) approval of Pharming’s Prior Approval Supplement to add the new Netherlands production facility of starting material to the Biologics License Application (BLA) to support its lead product, RUCONEST®.
Wilt u overschakelen naar een andere taal? Klik hier voor de Nederlandse website.